At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Necitumumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Necitumumab, Gemcitabine, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 61 participants across 17 sites in 7 countries.
Detailed Summary
The purpose of this study is to see how participants with late stage lung cancer do on gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the drugs are in combination and to see how long the medicine stays in the body. The study will last approximately 2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesCanada, France, Mexico, Netherlands, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartMar 2013
Primary CompletionAug 2014
Study CompletionDec 2015
TodayJul 2026
First PostedFeb 11, 2013
Enrollment StartMar 1, 2013
Primary CompletionAug 1, 2014
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.4 years ago
Interventions
Necitumumabdrug
Administered IV
Gemcitabinedrug
Administered IV
Cisplatindrug
Administered IV